Product Description
Treatment with Rocaltrol plus Caltrate D or Caltrate D for 12 months in elderly Chinese postmenopausal women effectively increased BMD at the lumbar spine. Rocaltrol plus Caltrate D was more effective at the lumbar spine than Caltrate D alone. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19262561/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Chile | Colombia | Czech | Denmark | Finland | Hungary | Ireland | Slovakia | Sweden | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Osteoporosis|Vitamin D Deficiency
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2200066020 |
ChiCTR2200066020 | N/A |
Not yet recruiting |
Osteoporosis |
2023-10-25 |
|||
NCT05370898 |
ZZ13-YQ-039 | N/A |
Unknown status |
Osteoporosis |
2022-12-01 |
2024-05-02 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR-IPR-15007081 |
ChiCTR-IPR-15007081 | N/A |
Completed |
Bone Cancer|Breast Cancer |
2016-03-06 |
|||
NCT02338713 |
Calcichew-1001 | P1 |
Completed |
Healthy Volunteers |
2015-02-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
2014-005619-18 |
2014-005619-18 | P4 |
Completed |
Osteoporosis|Vitamin D Deficiency |
2015-08-21 |
2022-03-13 |
Treatments |
|
NCT02457247 |
Calcichew-4001 | P4 |
Completed |
Vitamin D Deficiency |
2015-08-01 |
2024-06-06 |
Primary Endpoints|Treatments |
|
NCT00592917 |
OSTPRE-FPS | P4 |
Completed |
Osteoporosis |
2007-10-01 |
2025-02-07 |
Primary Endpoints|Treatments |